Our Editor Spotlight this week is Paolo A. Ascierto, MD (Paolo A. Ascierto), ESMO Open Editor for Melanoma. Dr. Ascierto’s work focuses on skin cancers, novel immunotherapies, cancer vaccines and molecular biomarkers for tumor progression in melanoma. esmo.org/about-esmo/bio…

The first edition of the I.N.N.O.V.A.T.E congress will be held in Naples on July 11th and 12th, 2024 - 3PSolution
Paolo A. Ascierto Christian Blank Liz Burton
oncodaily.com/39977.html

#Biomarkers #Cancer #Immunotherapy #OncoDaily #Oncology #Cancer Care

New #JITC article: Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial jitc.bmj.com/content/12/3/e… Jason Luke, MD, FACP Professor Georgina Long AO Paolo A. Ascierto…

Congrats Iovance Biotherapeutics with U.S. FDA approval of TIL therapy! Proud to be part of this revolution The Angeles Clinic Cancer at Cedars-Sinai The race is not over but we are closer Inderjit Mehmi Justin Moyers

CheckMate -67T trial investigating subcutaneous nivolumab (n=248) vs. IV Opdivo (n=247) noninferiority Bristol Myers Squibb ! Now everyone can get treated in the am ASCO #ASCOGU

I'm just going to place this here with the hopes of seeing you there to discuss and discover #Bridge24 Paolo A. Ascierto leads, we follow #worktodo #immunotherapy
melanomabridge.org

#Melanoma and #Immunotherapy Bridge Dec 4-7 hosted by Paolo A. Ascierto Naples, Italy bringing the best together to collaborate and educate
See you there to discuss major achievements and future discovery
Bernard A Fox IGOR PUZANOV

melanomabridge.org

Big Omid Hamid MD, as first Happy new year! You are faster than Speedy Gonzales ... I wanted to post this but you burned me! Thank you for posting our work. You are a great clinician and scientist, and you stay always on the top!BigOmid Hamid MD

#Bridge23 | Novità riguardanti tutti i diversi setting del trattamento del #melanoma , senza trascurare i primi dati assai promettenti dei vaccini a mRNA. Di tutto questo ci parla Paolo A. Ascierto.
Istituto Nazionale Tumori Pascale
oncoinfo.it/congressi/mela…

#Bridge23 | In this time of melanoma history neoadjuvant immunotherapy is rapidly becoming a standard treatment. But what will we see in the next future? We asked Professor Georgina Long AO.
Paolo A. Ascierto
oncoinfo.it/congressi/neoa…

#Bridge23 | #Biomarkers directing #melanoma immunotherapy: useful or not useful? We asked to explain pros and cons of both hypotheses (and some other things) to Alexander M.M. Eggermont and Jeffrey A. Sosman.
Paolo A. Ascierto
oncoinfo.it/congressi/biom…

#Bridge23 | Novel therapeutic options in the treatment of #melanoma : what should we expect in the next future? We asked Omid Hamid MD.
Paolo A. Ascierto
oncoinfo.it/congressi/mela…

#Bridge23 | Sequencing and beyond in the new era of target therapy in metastatic melanoma: where are we going in the next future? We asked Reinhard21035.
Paolo A. Ascierto
oncoinfo.it/congressi/a-ne…

#Bridge23 | Which role for imaging before and during cancer immunotherapy to assess Immunotherapy responsiveness? We asked Michael A. Postow.
Paolo A. Ascierto
oncoinfo.it/congressi/asse…

@Bridge23 | Could Artificial Intelligence be a useful tool in #melanoma diagnosis and research? And how? We asked Iman Osman.
Paolo A. Ascierto
oncoinfo.it/congressi/arti…

#Bridge23 | Online il secondo episodio della serie di podcast di Dr Talk Oncology #Immunotherapy & #Melanoma Bridge: la storia, i temi e i protagonisti.
Paolo A. Ascierto Istituto Nazionale Tumori Pascale

tinyurl.com/2zyhnx6z

#Bridge23 | Professor Georgina Long AO
Neoadjuvant #immunotherapy is becoming the standard of treatment for resectable #melanoma .

Paolo A. Ascierto Bernard A Fox Fondazione Melanoma Melanoma Institute Australia

First debate of the afternoon at #Bridge23 is Drs. Jeff Sosman vs Lex Eggermont re: usefulness of biomarkers for immunotherapy in melanoma. Here’s Jeff’s list of potentially useful biomarkers. Thoughts on how useful these are? OncoAlert Oncoinfo

#Bridge23 Society for Immunotherapy of Cancer Amazing to be in Naples w Paolo A. Ascierto for best #melanoma & #immunotherapy mtg of yr! Great science, clinically relevant discussions & reunion. Dinner tonight w mentors & mentees from >15 years of Memorial Sloan Kettering Cancer Center H/O fellowships. Brainstorming to #endcancer !

Alex Shoushtari, MD and Jason Luke, MD, FACP thumb wrestling on the debate stage in Italy over best treatment for mucosal melanoma. Bigger question- pocket square (Luke) or patterned shirt (Shoushtari)?